Ligand Pharmaceuticals Inc. — Q3 2014 Form 10-Q
Reporting period: Quarter and nine months ended September 30, 2014; comparisons are with the same 2013 periods. Ligand is a biopharmaceutical company focused on royalty-generating assets and Captisol formulation technology, working primarily through pharmaceutical partners.
Financial performance and position
| Metric | Q3 2014 | Q3 2013 | Nine months 2014 | Nine months 2013 |
|---|---|---|---|---|
| Total revenue | $15.0 million | $13.0 million | $41.5 million | $34.2 million |
| Operating income | $3.5 million | $3.1 million | $10.0 million | $8.5 million |
| Net income attributable to Ligand shareholders | $1.28 million | $1.97 million | $4.97 million | $9.55 million |
| Diluted EPS | $0.06 | $0.09 | $0.23 | $0.46 |
| Operating cash flow | Not reported quarterly | $10.3 million | $8.7 million |
- Revenue rose approximately 15% in Q3 and 21% year to date. Royalties were $7.5 million and $20.6 million, respectively; material sales were $6.3 million and $15.5 million.
- Calculated gross margin was approximately 90% for Q3 and 88% year to date, compared with approximately 80% and 87% in the prior-year periods. Operating margin was approximately 24% in both 2014 periods.
- Lower attributable net income reflected higher interest expense and fair-value charges for contingent liabilities; 2013 nine-month results also included a $2.6 million gain from discontinued operations. Q3 2014 consolidated net income was $0.8 million before the $0.5 million net loss attributable to noncontrolling interests; the corresponding nine-month figures were $4.2 million and $0.8 million.
- At September 30, cash and cash equivalents were $180.7 million, short-term investments $5.9 million, current assets $198.5 million and current liabilities $18.4 million. Working capital was $180.1 million.
- Ligand issued $245.0 million of 0.75% convertible senior notes due 2019; their net carrying amount was $193.6 million. The notes’ estimated fair value was $229.8 million. The prior term loan was fully repaid in July 2014. Cash plus short-term investments less note principal was approximately negative $58 million.
- Cash increased from $11.6 million at year-end 2013 to $180.7 million, mainly reflecting note proceeds. Financing activities provided $159.0 million; investing activities used $0.3 million.
Changes, outlook and material matters
- Royalty growth was driven mainly by Promacta and Kyprolis, partly offset by lower Avinza royalties after generic competition began in February 2014. Material sales increased year to date, primarily due to customer-purchase timing.
- Operating expenses rose, particularly R&D and G&A, with management citing increased stock-based compensation, Viking-related costs and business development activity. Nine-month stock-based compensation was $8.8 million, versus $4.1 million in 2013.
- Management believes available resources and expected operating receipts will fund anticipated operations and capital needs for at least 12 months, and expects cash to build. It cited Captisol sales, Promacta and Kyprolis royalties, product approvals and new licensing or milestone revenue. No quantitative revenue or earnings guidance is provided.
- Ligand entered a licensing and research collaboration with Omthera, potentially eligible for up to $44.5 million in payments plus tiered royalties, and licensed five programs to Viking. Ligand consolidated Viking as a variable-interest entity; Viking’s reported liabilities are without recourse to Ligand. Potential equity consideration from Viking financing had not been recorded.
- CyDex-related contingent liabilities were $12.9 million at quarter-end, with a $5.6 million fair-value increase recorded for the nine-month period. Estimates depend on uncertain product revenues, commercialization probabilities and milestones.
- The board authorized up to $200 million in share repurchases. Ligand repurchased 692,800 shares for $38.5 million during the quarter and another 110,000 shares for about $5.0 million through October 30, 2014.
- Key risks include reliance on Promacta, Kyprolis and Captisol-related revenues; Captisol’s sole-source supplier; partner discretion and termination rights; clinical and regulatory uncertainty; and potential dilution or cash demands under the convertible notes. Two lawsuits remained unresolved. In the securities litigation, the Third Circuit reversed the dismissal on October 17, 2014; Ligand said it would continue to defend the claims.
Investor verification priorities
- Confirm the sustainability and partner-level drivers of Promacta and Kyprolis royalties, Captisol sales, and the impact of generic Avinza competition.
- Review the convertible notes’ conversion, cash-settlement and dilution terms alongside the hedge and warrant transactions.
- Assess assumptions behind the $12.9 million CyDex contingent liability and the remaining Viking financing and licensing conditions.
- Track stock repurchases, cash generation and management’s expectation that liquidity will fund at least the next 12 months.
- Monitor the appeals-stage securities litigation and the separate attorneys’ fee lawsuit; outcomes were not determinable in the filing.